Tarsus Pharmaceuticals is growing revenue at 107% annually driven by its XDEMVY eye treatment, operates at an elite Rule of 40 score of 103, and analysts see 52% upside from $61.85, but extreme product concentration in one drug and an elevated put-to-call ratio of 22.55 signal the market is pricing in meaningful execution risk.
Thesis pillars
- Revenue Growth 107 Percent→Stable
- Elite Rule Of 40 Score→Stable
- Xdemvy Single Product Concentration→Stable
- +1 more pillar — see the Why tab for full reasoning
Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $67.89: Concentration risk — Product: XDEMVY; Concentration risk — Supplier: contract manufacturer in Europe.
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company with a single FDA-approved product, XDEMVY (lotilaner ophthalmic solution 0.25%), for the treatment of Demodex blepharitis — the first FDA-approved treatment for this condition, launched August 2023. XDEMVY... Read more
Sell if holding. Multiple concerning factors at $67.89: Concentration risk — Product: XDEMVY; Concentration risk — Supplier: contract manufacturer in Europe. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.0/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 34d clear, semi cycle peak clear, materials cycle peak clear). Fails on news legal. Suitability: speculative.
About Tarsus Pharmaceuticals, Inc.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals launched XDEMVY (lotilaner ophthalmic solution) in August 2023, the month following FDA approval in July 2023, as the first and only FDA-approved treatment for Demodex blepharitis in a U.S. patient population estimated at approximately 25 million. Cumulative net product sales exceeded $646 million through the launch-to-date period, while net losses narrowed to $66.4 million in 2025 from $115.6 million in 2024 as commercial revenue scaled.
Tarsus generates revenue exclusively from U.S. XDEMVY sales through specialty pharmacy channels, targeting ophthalmologists and optometrists with a specialty sales force, key opinion leader education, and direct-to-consumer television campaigns initiated in 2025. The treatment course is 6 weeks of twice-daily dosing; approximately 40% of patients had Demodex recurrence at one year in Saturn-1 extension data, supporting a retreatment market — current retreatment rates run in the low double-digits with a long-term rate projected at approximately 20%. Internationally, Tarsus licensed TP-03 to GrandPharma for the China Territory, with GrandPharma targeting approval in 2026; Tarsus aims for a preservative-free European formulation approval in 2027 and is in regulatory discussions with Japan. XDEMVY is filled and finished by a single contract manufacturer in Europe, with Tarsus in discussions to qualify a second U.S.-based manufacturer. The company has no direct commercial peer, as XDEMVY holds the only FDA-approved pharmacologic therapy for Demodex blepharitis.
Show full overview
Tarsus's near-term pipeline value rests on two binary clinical readouts beyond the XDEMVY revenue base: TP-04 for ocular rosacea (Phase 2 initiated December 2025, topline results expected in the first half of 2027) and TP-05 for Lyme disease prophylaxis (Phase 2 targeted to initiate in the second quarter of 2026, with FDA having agreed to the proposed Phase 2 design). If either program fails to advance, the company's long-term value compresses to the retreatment-driven XDEMVY stream, subject to single-CMO supply risk in Europe and reimbursement conditions.
See also: Healthcare · Biotechnology
From Tarsus Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-07-05Recent Developments — Tarsus Pharmaceuticals, Inc.
Latest news
- NEWS Earnings call transcript: Tarsus Pharmaceuticals Q1 2026 beats EPS forecast, stock dips - Investing.com Australia — Investing.com Australia positive
- NEWS Earnings call transcript: Tarsus Pharmaceuticals Q1 2026 beats EPS forecast, stock dips - Investing.com Canada — Investing.com Canada positive
- NEWS Earnings call transcript: Tarsus Pharmaceuticals Q1 2026 beats EPS forecast, stock dips - Investing.com — Investing.com positive
- NEWS Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance Australia — Yahoo Finance Australia positive
- NEWS Tarsus (TARS) Q1 2026 Earnings Transcript - The Globe and Mail — The Globe and Mail positive
Generated 2026-07-05T20:10:29Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductXDEMVY10-K Item 1A: 'a single product approved for commercial sale ... We have one product, XDEMVY®'
- HIGHSuppliercontract manufacturer in Europe10-K Item 1A: 'XDEMVY is currently being filled and finished by a reputable contract manufacturer in Europe'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $67.89: Concentration risk — Product: XDEMVY; Concentration risk — Supplier: contract manufacturer in Europe. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $60.86. Score 6.0/10, moderate confidence.
Take-profit target: $81.88 (+25.1% upside). Prior stop was $60.86. Stop-loss: $60.86.
Concentration risk — Product: XDEMVY; Concentration risk — Supplier: contract manufacturer in Europe; Consecutive earnings misses (2).
Tarsus Pharmaceuticals, Inc. trades at a P/E of N/A (forward 22.8). TrendMatrix value score: 7.6/10. Verdict: Sell.
15 analysts cover TARS with a consensus score of 4.4/5. Average price target: $94.
What does Tarsus Pharmaceuticals, Inc. do?Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company with a single FDA-approved product, XDEMVY...
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company with a single FDA-approved product, XDEMVY (lotilaner ophthalmic solution 0.25%), for the treatment of Demodex blepharitis — the first FDA-approved treatment for this condition, launched August 2023. XDEMVY generated more than $646 million in cumulative net product sales; pipeline includes TP-04 (ocular rosacea, Phase 2 initiated December 2025) and TP-05 (Lyme disease prophylaxis, Phase 2 planned Q2 2026).